☰

Mina Nikanjam, Ph.D. - Publications

Affiliations: 
2007 University of California, Berkeley, Berkeley, CA, United States 
Tree Info Similar researchers PubMed Report error

34 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Nikanjam M, Tinajero J, McGann M, Li J, Yang J, Shen F, Sicklick JK, Kato S, Capparelli E, Kurzrock R. Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San Diego. Journal of Hematology Oncology Pharmacy. 13: 19-25. PMID 36998525  0.31
2020 Charo LM, Eskander RN, Okamura R, Patel SP, Nikanjam M, Lanman RB, Piccioni DE, Kato S, McHale MT, Kurzrock R. Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. Molecular Oncology. PMID 32881280 DOI: 10.1002/1878-0261.12791  0.301
2020 Li J, Nikanjam M, Cunningham CK, McFarland EJ, Coates EE, Houser KV, Lin BC, McDermott AB, Flach B, Gama L, Koup RA, Graham BS, Mascola JR, Ledgerwood JE, Capparelli EV. Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. Clinical Pharmacology and Therapeutics. PMID 32866318 DOI: 10.1002/Cpt.2026  0.34
2020 Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treatment Reviews. 86: 102019. PMID 32251926 DOI: 10.1016/J.Ctrv.2020.102019  0.349
2020 Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, Papanicolau-Sengos A, Lenzo FL, Morrison C, Kurzrock R. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology. 9: 1708065. PMID 32117584 DOI: 10.1080/2162402X.2019.1708065  0.304
2020 Jardim DL, De Melo Gagliato D, Nikanjam M, Barkauskas DA, Kurzrock R. Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. Oncoimmunology. 9: 1710052. PMID 32002305 DOI: 10.1080/2162402X.2019.1710052  0.351
2019 Poddar S, Capparelli EV, Rosser EW, Gipson RM, Wei L, Le T, Jung ME, Radu C, Nikanjam M. Development and preclinical pharmacology of a novel dCK inhibitor, DI-87. Biochemical Pharmacology. 113742. PMID 31812677 DOI: 10.1016/J.Bcp.2019.113742  0.341
2019 Kawakatsu S, Nikanjam M, Lin M, Le S, Saunders I, Kuo DJ, Capparelli EV. Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemotherapy and Pharmacology. PMID 31586225 DOI: 10.1007/S00280-019-03966-4  0.354
2019 Nikanjam M, Arguello D, Gatalica Z, Swensen J, Barkauskas DA, Kurzrock R. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden, and PD-L1 expression in cancer patients. International Journal of Cancer. PMID 31479512 DOI: 10.1002/Ijc.32661  0.307
2019 Yang J, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Stoch SA, Bertino JS, Nafziger AN, Ma JD. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults. Journal of Clinical Pharmacology. PMID 31051051 DOI: 10.1002/Jcph.1440  0.304
2019 Nikanjam M, Yang J, Capparelli EV. Abstract 3892: Population pharmacokinetics of siltuximab: An analysis across tumor types Cancer Research. 79: 3892-3892. DOI: 10.1158/1538-7445.Sabcs18-3892  0.386
2019 Poddar S, Nikanjam M, Capparelli E, Le T, Wei L, Radu C. Abstract 3881: Relating tumor drug concentrations to target effect with semi physiologic PK-PD modeling in drug development: An application using a novel dCK inhibitor Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3881  0.37
2019 Nikanjam M, Arguello D, Gatalica Z, Barkauskas DA, Kurzrock R. Abstract 4928: Relationship between protein biomarkers of potential chemotherapy response and microsatellite status, tumor mutational burden, and PD-L1 expression in patients with cancer Cancer Research. 79: 4928-4928. DOI: 10.1158/1538-7445.Am2019-4928  0.32
2018 Nikanjam M, Wing J, Capparelli E, Kurzrock R. Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience. Cureus. 10: e3634. PMID 30705793 DOI: 10.7759/Cureus.3634  0.344
2018 Yang J, Nikanjam M, Best BM, Pinto J, Chadwick EG, Daar ES, Havens PL, Rakhmanina N, Capparelli EV. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood. Journal of Clinical Pharmacology. PMID 30252146 DOI: 10.1002/Jcph.1293  0.347
2018 Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R. Advanced Basal Cell Cancer: Concise Review of Molecular Characteristics and Novel Targeted and Immune Therapeutics. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30219896 DOI: 10.1093/Annonc/Mdy412  0.362
2018 Nikanjam M, Sun A, Albers M, Mangalindin K, Song E, Vempaty H, Sam D, Capparelli EV. Vincristine-associated Neuropathy With Antifungal Usage: A Kaiser Northern California Experience. Journal of Pediatric Hematology/Oncology. PMID 29771861 DOI: 10.1097/Mph.0000000000001220  0.35
2018 Yang J, Patel M, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Aubrey Stoch S, Bertino JS, Nafziger AN, Ma JD. Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach. Journal of Clinical Pharmacology. PMID 29663428 DOI: 10.1002/Jcph.1125  0.306
2018 Nikanjam M, Arguello D, Gatalica Z, Barkauskas DA, Kurzrock R. Relationship between protein biomarkers of potential chemotherapy response and microsatellite status in 28,101 cancer patients. Journal of Clinical Oncology. 36: e24259-e24259. DOI: 10.1200/Jco.2018.36.15_Suppl.E24259  0.308
2017 Nikanjam M, Capparelli EV, Lancet JE, Louie A, Schiller G. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. Cancer Chemotherapy and Pharmacology. PMID 29167924 DOI: 10.1007/S00280-017-3484-5  0.322
2017 Nikanjam M, Patel H, Kurzrock R. Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. Oncoimmunology. 6: e1338997. PMID 28920006 DOI: 10.1080/2162402X.2017.1338997  0.395
2017 Nikanjam M, Liu S, Yang J, Kurzrock R. Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. The Oncologist. PMID 28424323 DOI: 10.1634/Theoncologist.2016-0357  0.404
2017 Nikanjam M, Patel H, Kurzrock R. Dosing immunotherapy combinations: Analysis of 3,526 patients in cancer clinical trials. Journal of Clinical Oncology. 35: e14620-e14620. DOI: 10.1200/Jco.2017.35.15_Suppl.E14620  0.403
2017 Nikanjam M, Poddar S, Capparelli E, Le T, Wei L, Radu C. Abstract 4064: Relating tumor drug concentrations to target effect with semi-physiologic PK-PD modeling in drug development: an application using a novel dCK inhibitor Cancer Research. 77: 4064-4064. DOI: 10.1158/1538-7445.Am2017-4064  0.401
2016 Nikanjam M, Liu S, Kurzrock R. Dosing Targeted and Cytotoxic Two-Drug Combinations: Lessons Learned from Analysis of 24,326 Patients Reported 2010 through 2013. International Journal of Cancer. PMID 27389805 DOI: 10.1002/Ijc.30262  0.409
2016 Liu S, Nikanjam M, Kurzrock R. Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. Oncotarget. PMID 26824502 DOI: 10.18632/Oncotarget.7023  0.423
2016 Nikanjam M, Liu S, Kurzrock R. Dosing de novo two-drug combinations based on 32,894 patients in phase I-III clinical trials. Journal of Clinical Oncology. 34: 2563-2563. DOI: 10.1200/Jco.2016.34.15_Suppl.2563  0.411
2016 Nikanjam M, Capparelli E, Lancet JE, Kolitz JE, Louie AC, Schiller GJ. Enhanced Cytarabine and Daunorubicin Population Pharmacokinetics When Administered As CPX-351: A Novel Liposomal Formulation Not Requiring Dose Reduction for Mild Renal or Hepatic Dysfunction Blood. 128: 3955-3955. DOI: 10.1182/Blood.V128.22.3955.3955  0.392
2013 Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Capparelli EV. Abstract 3365: Population pharmacokinetics of oxaliplatin: An analysis across human development in infants, children and adults.: Cancer Research. 73: 3365-3365. DOI: 10.1158/1538-7445.Am2013-3365  0.373
2012 Nikanjam M, Kabamba D, Cressey TR, Burger D, Aweeka FT, Acosta EP, Spector SA, Capparelli EV. Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrobial Agents and Chemotherapy. 56: 5374-80. PMID 22869579 DOI: 10.1128/Aac.00842-12  0.373
2012 Nikanjam M, Chadwick EG, Robbins B, Alvero C, Palumbo P, Yogev R, Pinto J, Hazra R, Hughes ML, Heckman BE, Capparelli EV. Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing. Clinical Pharmacology and Therapeutics. 91: 243-9. PMID 22190064 DOI: 10.1038/Clpt.2011.218  0.359
2012 Tremoulet AH, Nikanjam M, Cressey TR, Chokephaibulkit K, McKinney R, Mirochnick M, Capparelli EV. Developmental pharmacokinetic changes of Lamivudine in infants and children. Journal of Clinical Pharmacology. 52: 1824-32. PMID 22180560 DOI: 10.1177/0091270011426563  0.376
2007 Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. Journal of Controlled Release : Official Journal of the Controlled Release Society. 124: 163-71. PMID 17964677 DOI: 10.1016/J.Jconrel.2007.09.007  0.543
2007 Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF, Forte TM. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. International Journal of Pharmaceutics. 328: 86-94. PMID 16959446 DOI: 10.1016/J.Ijpharm.2006.07.046  0.533
Show low-probability matches.